A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma

Hematological Oncology

Volumn 27, Issue 1, 2009, Pages 17-22

  Sondergaard, T E ^a   Pedersen, P T ^a   Andersen, T L ^a   Soe K ^a   Lund, T ^a   Ostergaard B ^a   Gamero, P ^b   Delaisse, J M ^a   Plesner, Torhen ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b INSERM   (France)

Author keywords

Bone; Bone markers; Multiple myeloma; Osteoclast; Statin; TRACP

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; DICKKOPF 1 PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; OSTEOCALCIN; OSTEOPROTEGERIN; PEPTIDE FRAGMENT; SIMVASTATIN; ZOLEDRONIC ACID; ANTILIPEMIC AGENT;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE METABOLISM; BONE TURNOVER; CELL ACTIVITY; CELL STIMULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE DISEASE; MYALGIA; NAUSEA; NEUTROPENIA; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; TENDINITIS; VOMITING; BONE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; METABOLISM; MIDDLE AGED; PATIENT SELECTION;

AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; BONE AND BONES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOCLASTS; PATIENT SELECTION; SIMVASTATIN;

EID: 65249130676     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.869     Document Type: Article

References (37)

1. Rajkumar SV, Kyle RA. Multiple myeloma: diagnosis and treatment. Mayo Clin Proc 2005; 80: 1371-1382.
2. Horiuchi N, Maeda T. Statins and bone metabolism. Oral Dis 2006; 12: 85-101.
3. Boissy P, Andersen TL, Abdallah BM, Kassem M, Plesner T, Delaisse JM. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. Cancer Res 2005; 65: 9943-9952.
4. Terpos E, Sezer O, Croucher P, Dimopoulos MA. Myeloma bone disease and proteasome inhibition therapies. Blood 2007; 110: 1098-1104.
5. Hindler K, Cleeland CS, Rivera E, Collard CD. The role of statins in cancer therapy. Oncologist 2006; 11: 306-315.
6. van de Donk NW, Kamphuis MM, Lokhorst HM, Bloem AC. The cholesterol lowering drug lovastatin induces cell death in myeloma plasma cells. Leukemia 2002; 16: 1362-1371.
7. Osadchy A, Drucker L, Radnay J, Shapira H, Lishner M. Microenvironment factors do not afford myeloma cell lines protection from simvastatin. Eur J Haematol 2004; 73: 183-190.
8. van de DonkNW, Kamphuis MM, van KB, Lokhorst HM, Bloem AC. Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood 2003; 102: 3354-3362.
9. Drucker L, Afensiev F, Radnay J, Shapira H, Lishner M. Co-administration of simvastatin and cytotoxic drugs is advantageous in myeloma cell lines. Anticancer Drugs 2004; 15: 79-84.
10. van de Donk NW, Bloem AC, van der SE, Lokhorst HM. New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathway. Curr Pharm Des 2006; 12: 327-340.
11. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 1946-1949.
12. Maeda T, Matsunuma A, Kawane T, Horiuchi N. Simvastatin promotes osteoblast differentiation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 2001; 280: 874-877.
13. Maeda T, Kawane T, Horiuchi N. Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology 2003; 144: 681-692.
14. Staal A, Frith JC, French MH, et al. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 2003; 18: 88-96.
15. Woo JT, Kasai S, Stern PH, Nagai K. Compactin suppresses bone resorption by inhibiting the fusion of prefusion osteoclasts and disrupting the actin ring in osteoclasts. J Bone Miner Res 2000; 15: 650-662.
16. Edwards CJ, Russell RG, Spector TD. Statins and bone: myth or reality? Calcif Tissue Int 2001; 69: 63-66.
17. Rizzo M, Rini GB. Statins, fracture risk, and bone remodeling: What is true? Am J Med Sci 2006; 332: 55-60.
18. Rejnmark L, Buus NH, Vestergaard P, et al. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women. J Bone Miner Res 2004; 19: 737-744.
19. Rosenson RS, Tangney CC, Langman CB, Parker TS, Levine DM, Gordon BR. Short-term reduction in bone markers with high-dose simvastatin. Osteoporos Int 2005; 16: 1272-1276.
20. Stein EA, Farnier M, Waldstreicher J, Mercuri M. Effects of statins on biomarkers of bone metabolism: a randomised trial. Nutr Metab Cardiovasc Dis 2001; 11: 84-87.
21. Chan MH, Mak TW, Chiu RW, Chow CC, Chan IH, Lam CW. Simvastatin increases serum osteocalcin concentration in patients treated for hypercholesterolaemia. J Clin Endocrinol Metab 2001; 86: 4556-4559.
22. Montagnani A, Gonnelli S, Cepollaro C, et al. Effect of simvastatin treatment on bone mineral density and bone turnover in hypercholesterolemic postmenopausal women: a 1-year longitudinal study. Bone 2003; 32: 427-433.
23. Oxlund H, Dalstra M, Andreassen TT. Statin given perorally to adult rats increases cancellous bone mass and compressive strength. Calcif Tissue Int 2001; 69: 299-304.
24. Oxlund H, Andreassen TT. Simvastatin treatment partially prevents ovariectomy-induced bone loss while increasing cortical bone formation. Bone 2004; 34: 609-618.
25. van der SE, Bloem AC, van de Donk NW, et al. Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica 2006; 91: 542-545.
26. Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 1996; 2: 483-491.
27. Kornbrust DJ, MacDonald JS, Peter CP, et al. Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits. J Pharmacol Exp Ther 1989; 248: 498-505.
28. Kim WS, Kim MM, Choi HJ, et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest New Drugs 2001; 19: 81-83.
29. Larner J, Jane J, Laws E, Packer R, Myers C, Shaffrey M. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol 1998; 21: 579-583.
30. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115-1123.
31. Yavasoglu I, Tombuloglu M, Kadikoylu G, Donmez A, Cagirgan S, Bolaman Z. Cholesterol levels in patients with multiple myeloma. Ann Hematol 2007.
32. Garrett IR, Gutierrez G, Mundy GR. Statins and bone formation. Curr Pharm Des 2001; 7: 715-736.
33. Thompson K, Rogers MJ. Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro. J Bone Miner Res 2004; 19: 278-288.
34. Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S. Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol 2001; 21: 1636-1641.
35. von SD, Fish S, Yahalom D, et al. Does simvastatin stimulate bone formation in vivo? BMC Musculoskelet Disord 2003; 4: 8.
36. Yao W, Farmer R, Cooper R, et al. Simvastatin did not prevent nor restore ovariectomy-induced bone loss in adult rats. J Musculoskelet Neuronal Interact 2006; 6: 277-283.
37. Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin [clarithromycin]/Revlimid[lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008; 111: 1101-1109.